2. Academic Validation
  3. Mutagenicity and teratogenicity studies of vitacoxib in rats and mice

Mutagenicity and teratogenicity studies of vitacoxib in rats and mice

  • Toxicol Rep. 2018 Aug 13:5:827-831. doi: 10.1016/j.toxrep.2018.08.007.
Jianzhong Wang 1 2,  Feifei Sun 1 2,  Shusheng Tang 1 2,  Suxia Zhang 1 2,  Jing Li 3,  Xingyuan Cao 1 2 4
Affiliations

Affiliations

  • 1 Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, China Agricultural University, Beijing 100193, People's Republic of China.
  • 2 Laboratory of Quality & Safety Risk Assessment for Animal Products on Chemical Hazards (Beijing), Ministry of Agriculture, Beijing 100193, People's Republic of China.
  • 3 Beijing Orbiepharm Co. Ltd., Beijing 100185, People's Republic of China.
  • 4 Key Laboratory of Detection for Veterinary Drug Residues and Illegal Additives, Ministry of Agriculture, Beijing 100193, People's Republic of China.
PMID: 30128300 DOI: 10.1016/j.toxrep.2018.08.007
Abstract

Vitacoxib is a new drug candidate for treatment of inflammation, pain and fever as selective cyclooxygenase-2 inhibitors. In the current study, the mice sperm abnormality, mammalian erythrocyte micronucleus and in vivo chromosome aberration, and teratogenicity in SD rats were evaluated. Vitacoxib did not cause an increase in the frequency of structural chromosome aberrations, nor did it produce an increase in the number of micro nucleated polychromatic erythrocytes at dose of 1250-5000 mg/kg body weight (BW). There were no toxicological signs observed in teratogenicity test in female SD rats at dose of 200-5000 mg/kg BW. Based on these results of these studies, vitacoxib does not appear to be observed mutagenicity and teratogenicity.

Keywords

Coxib; Mutagenicity; Safety evaluation; Teratogenicity; Toxicity studies; Vitacoxib.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z